GA
RPRX icon

Greytown Advisors’s Royalty Pharma RPRX Stock Holding History

Greytown Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$1.9M Buy
72,196
+218
+0.3% +$6.04K 1.12% 19
2024
Q1 		$2.19M Sell
71,978
-2,812
-4% -$82.9K 1.23% 16
2023
Q4 		$2.1M Buy
74,790
+189
+0.3% +$5.19K 1.12% 18
2023
Q3 		$2.02M Buy
74,601
+5,410
+8% +$161K 1.12% 18
2023
Q2 		$2.13M Buy
69,191
+593
+0.9% +$20.1K 1.16% 16
2023
Q1 		$2.47M Buy
68,598
+13,917
+25% +$516K 1.28% 17
2022
Q4 		$2.16M Buy
54,681
+4,208
+8% +$176K 1.17% 17
2022
Q3 		$2.03M Sell
50,473
-83,036
-62% -$3.55M 1.23% 17
2022
Q2 		$5.61M Buy
133,509
+2,366
+2% +$97K 3.18% 8
2022
Q1 		$5.11M Buy
131,143
+4,260
+3% +$167K 2.47% 11
2021
Q4 		$5.06M Buy
126,883
+20,562
+19% +$799K 2.15% 12
2021
Q3 		$3.84M Buy
+106,321
New +$4.13M 1.71% 11

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Greytown Advisors's RPRX Position: Q2 2024 in Review

Greytown Advisors increased its Royalty Pharma (RPRX) stake by 0.3% in Q2 2024, buying an estimated $6.04K and bringing the position to 72,196 shares worth $1.9M. The position accounts for 1.12% of the portfolio, ranked #19.

Greytown Advisors first reported a position in RPRX in Q3 2021 and has held it in 12 quarters since. The position peaked at $5.61M in Q2 2022. 378 funds tracked by Wall St. Rank hold RPRX as of Q2 2024.

  • Greytown Advisors held 72,196 shares of Royalty Pharma worth $1.9M as of Q2 2024.
  • Greytown Advisors bought 218 Royalty Pharma shares in Q2 2024, an estimated $6.04K.
  • Royalty Pharma made up 1.12% of Greytown Advisors's portfolio in Q2 2024, its #19 holding.
  • Greytown Advisors first reported a position in Royalty Pharma in Q3 2021 and has held it in 12 quarters since.
  • Greytown Advisors's Royalty Pharma position peaked at $5.61M in Q2 2022.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2024.

Based on Greytown Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.